“In a major trial, patients given low-dose diranersen injections showed 54 per cent less decline on a test of memory and thinking over almost two years. The findings suggest that the treatment could prove the most powerful to slow Alzheimer’s yet.

It is also the first to show a reduction in tau, a protein that forms damaging tangles linked to brain cell death. The treatment uses gene-silencing technology to tackle disease at its source, blocking the RNA messages that tell brain cells to produce tau…

The strongest results came from the group of 60 patients given the lowest dose – 60mg every 24 weeks – through an injection into the spinal fluid in the lower back… On the test of memory and thinking, patients in the lowest-dose group showed 54 per cent less decline at 96 weeks. On a broader measure, which also assessed how well patients managed everyday tasks, the difference was 38 per cent.

The findings suggest a potentially greater effect than existing Alzheimer’s drugs. Lecanemab, one of two recently licensed treatments, slowed clinical decline by 27 per cent in trials, while donanemab achieved 35 per cent on a different measure. However, the results cannot be directly compared because the studies used different methods and patient groups.”

From Telegraph.